About the index

The PII aims at ranking companies in their ability to bring products from Phase I/II to market and commercialize them successfully, and utilizes a range of clinical, regulatory and commercial metrics to do this, ranging from the corporate level down to individual products.

Sources include company websites, third party institutions (e.g. FDA, clinicaltrials.gov), syndicated and analyst reports, etc, which are analyzed and rolled up at company level for innovation and commercialization and ranked.

It is important to note that each metric, measure or index must exist (somewhere), be gettable (either full or derivable), be useable (compare like with like, transferable), be available across ALL companies under consideration.

Fuller details are available in the PII White Paper, which discusses in greater depth the metrics themselves and also highlights where individual companies excel, or do poorly.

Access the White Papers

IDEA Pharma’s Pharmaceutical Innovation Index, and its accompanying White Paper, explore the performance of individual companies in much greater detail. By accessing our White Papers, you are given an inside look into our research and findings.

  • 1Methodology and analysis
  • 2Extended profiles of the Top 10 overall companies
  • 3White Papers from 2019, 2018, 2017, 2016, 2015, and 2014

Have an opinion?

We’d love to hear your thoughts. We are open to further discussion and encourage questions and comments about our rankings. Please give a shout to continue the conversation, we are here to answer.

Have an opinion?